Literature DB >> 12685521

Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies.

M Huss1, U Lehmkuhl.   

Abstract

This article reviews pharmacological, animal, and human evidence regarding the abuse liability of methylphenidate (MPH). Findings are not always consistent, but evidence converges to suggest that although intravenous methylphenidate has some abuse potential, there is very little potential for oral MPH abuse. Furthermore, the available data suggests that children with Attention-Deficit/Hyperactivity Disorder (ADHD) who are treated with MPH are at lower risk for substance use disorder later in life. More longitudinal, prospective studies are needed to assess the long term effects of MPH treatment in ADHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685521     DOI: 10.1177/070674370200601s09

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  16 in total

1.  Use of stimulants for attention deficit hyperactivity disorder: FOR.

Authors:  David Coghill
Journal:  BMJ       Date:  2004-10-16

2.  Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.

Authors:  Nicholas King; Samuel Floren; Natasha Kharas; Ming Thomas; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2019-06-19       Impact factor: 3.533

3.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 4.  Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.

Authors:  Howard Schubiner
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  The effect of ADHD on the life of an individual, their family, and community from preschool to adult life.

Authors:  V A Harpin
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

Review 6.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

8.  European clinical guidelines for hyperkinetic disorder -- first upgrade.

Authors:  Eric Taylor; Manfred Döpfner; Joseph Sergeant; Philip Asherson; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Aribert Rothenberger; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 9.  Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome.

Authors:  Lily Hechtman; Brian Greenfield
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Behnaz Shabab; Sulail Fatima
Journal:  J Neural Transm (Vienna)       Date:  2016-09-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.